

## Recombinant Human EphB6 Protein (Fc Tag)

Catalog No. PKSH031775

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


### Description

<b>Synonyms</b>	HEP
<b>Species</b>	Human
<b>Expression Host</b>	HEK293 Cells
<b>Sequence</b>	Met 1-Ser 579
<b>Accession</b>	NP_004436.1
<b>Calculated Molecular Weight</b>	86.5 kDa
<b>Observed molecular weight</b>	100-110 kDa
<b>Tag</b>	C-hFc
<b>Bioactivity</b>	<ol style="list-style-type: none"> <li>1. Immobilized recombinant human EphrinB1 at 10 µg/ml (100 µl/well) can bind human EphB6 with a linear range of 0.16-4 µg/ml.</li> <li>2. Immobilized recombinant human EphrinB2 at 10 µg/ml (100 µl/well) can bind human EphB6 with a linear range of 1. 28-32 ng/ml.</li> </ol>

### Properties

<b>Purity</b>	> 90 % as determined by reducing SDS-PAGE.
<b>Endotoxin</b>	< 1.0 EU per µg of the protein as determined by the LAL method.
<b>Storage</b>	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
<b>Shipping</b>	This product is provided as lyophilized powder which is shipped with ice packs.
<b>Formulation</b>	<p>Lyophilized from sterile PBS, pH 7.4</p> <p>Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.</p> <p>Please refer to the specific buffer information in the printed manual.</p>
<b>Reconstitution</b>	Please refer to the printed manual for detailed information.

### Data



> 90 % as determined by reducing SDS-PAGE.

### For Research Use Only

## Background

Ephrins are divided into the ephrin-A (EFNA) class and the ephrin-B (EFNB) class based on their structures and sequence relationships. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. EphB6 is an unusual Eph receptor; lacking catalytic capacity due to alterations in its kinase domain. Interestingly; increased metastatic activity is associated with reduced EphB6 receptor expression in several tumor types; including breast cancer. This emphasizes the potential of EphB6 to act as a suppressor of cancer aggressiveness. EphB6 suppress cancer invasiveness through c-Cbl-dependent signaling; morphologic changes; and cell attachment and indicate that EphB6 may represent a useful prognostic marker and a promising target for therapeutic approaches. EphB6 can both positively and negatively regulate cell adhesion and migration; and suggest that tyrosine phosphorylation of the receptor by an Src family kinase acts as the molecular switch for the functional transition. In addition; Ephrin-B2 may be a physiological ligand for the EphB6 receptor.

## For Research Use Only